Company Overview - Frontera Therapeutics has submitted a listing application to the Hong Kong Stock Exchange, with UBS and Haitong International as joint sponsors [1] - The company's core business focuses on the development of innovative recombinant adeno-associated virus (rAAV) gene therapies, particularly targeting ophthalmic and cardiovascular diseases [1] - Frontera Therapeutics' product pipeline is considered to have best-in-class potential globally [1] Product Pipeline - As of December 16, 2025, Frontera Therapeutics' product pipeline includes eight self-developed rAAV gene therapy candidates [1] - The two core products are FT-002 for treating X-linked retinitis pigmentosa (XLRP) and FT-003 for treating neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME) [1] Competitive Advantages - The company possesses the AAVANCETM Bac/Sf9 production platform, which enables safe, scalable, and cost-effective high-quality production [1] - Frontera Therapeutics also has the EXACTETM proprietary rAAV gene therapy R&D platform, supporting the development of innovative products protected by global intellectual property rights [1] Regulatory Approvals - Frontera Therapeutics has received a total of 12 IND approvals from the National Medical Products Administration and the FDA, making it the company with the most IND approvals for rAAV gene therapy development in China [1] - The company has successfully advanced three candidate drugs into Phase II clinical trials [1] Industry Growth - The global gene therapy market is projected to grow from $2.8 billion in 2024 to $32 billion by 2035 [2] - The Chinese gene therapy market is also expected to experience rapid growth, reaching a market size of RMB 11.6 billion by 2035 [2]
Frontera Therapeutics递表港交所 联席保荐人为瑞银和海通国际